NASDAQ:MDCO - The Medicines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$19.95 +0.15 (+0.76 %)
(As of 01/18/2019 08:00 AM ET)
Previous Close$19.80
Today's Range$19.45 - $20.24
52-Week Range$16.69 - $41.57
Volume1.22 million shs
Average Volume1.36 million shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.06
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States. It primarily focuses on developing Inclisiran, a lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.79 million
Book Value$0.34 per share

Profitability

Net Income$-708,370,000.00
Net Margins-668.93%

Miscellaneous

Employees170
Market Cap$1.46 billion
OptionableOptionable

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) posted its quarterly earnings results on Thursday, November, 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.13. The business had revenue of ($3.30) million for the quarter, compared to the consensus estimate of $1.88 million. The Medicines had a negative return on equity of 1,477.75% and a negative net margin of 668.93%. The Medicines's quarterly revenue was down 141.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.19) earnings per share. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

9 brokers have issued 12 month price objectives for The Medicines' stock. Their predictions range from $25.00 to $85.00. On average, they anticipate The Medicines' share price to reach $50.3750 in the next twelve months. This suggests a possible upside of 152.5% from the stock's current price. View Analyst Price Targets for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.

Has The Medicines been receiving favorable news coverage?

Media headlines about MDCO stock have trended somewhat positive on Friday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. The Medicines earned a news impact score of 0.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.

Are investors shorting The Medicines?

The Medicines saw a increase in short interest in December. As of December 31st, there was short interest totalling 21,058,863 shares, an increase of 15.7% from the December 14th total of 18,202,318 shares. Based on an average daily volume of 1,732,879 shares, the days-to-cover ratio is currently 12.2 days. Approximately 29.9% of the shares of the company are short sold. View The Medicines' Current Options Chain.

Who are some of The Medicines' key competitors?

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Mr. Christopher T. Cox, Chief Corp. Devel. Officer and Exec. VP (Age 54)
  • Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
  • Mr. William B. O'Connor, Special Advisor to the Chief Exec. Officer (Age 60)
  • Mr. Mark Timney, CEO & Director

Who are The Medicines' major shareholders?

The Medicines' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include First Midwest Bank Trust Division (0.09%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.03%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Mark Timney, Melvin K Spigelman, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines.

Which institutional investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC and Louisiana State Employees Retirement System. Company insiders that have sold The Medicines company stock in the last year include Armin M Kessler, Clive Meanwell, Melvin K Spigelman and William Crouse. View Insider Buying and Selling for The Medicines.

Which institutional investors are buying The Medicines stock?

MDCO stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division and State of Alaska Department of Revenue. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox, Fredric N Eshelman and Mark Timney. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $19.95.

How big of a company is The Medicines?

The Medicines has a market capitalization of $1.46 billion and generates $44.79 million in revenue each year. The company earns $-708,370,000.00 in net income (profit) each year or ($8.40) on an earnings per share basis. The Medicines employs 170 workers across the globe.

What is The Medicines' official website?

The official website for The Medicines is http://www.themedicinescompany.com.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  430 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  747
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel